About this trial
Brain abscess is a severe intracranial infection associated with significant morbidity and mortality. Standard management combines neurosurgical intervention, when feasible, with prolonged intravenous antibiotic therapy. Neurosurgical procedures, such as surgical drainage or stereotactic aspiration, play a key role in reducing intracranial pressure, decreasing the infectious burden, and obtaining samples for microbiological identification.
However, neurosurgical intervention is not always possible due to technical limitations or patien related contrindications. In these situations, microbiological documentation becomes particularly challenging. Conventional diagnostic methods have limited sensitivity, with blood cultures and lumbar puncture yielding positive results in only about 25% of brain abscess cases.
Recent advances in infectious disease diagnostics have introduced metagenomic approaches that may improve pathogen detection. Studies have shown that metagenomic analysis of operative samples can provide more comprehensive microbiological documentation than conventional culture-based methods. In addition, next-generation sequencing (NGS) of circulating microbial cell-free DNA in blood enables the detection of short microbial DNA fragments with a short half-life, reflecting active infection. This technology has already demonstrated promising results in clinical situations where microbiological documentation is difficult, such as febrile neutropenia. The present study aims to evaluate the performance of this approach in patients with brain abscess.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Participant ≥ 18 years of age.
Participant presenting with a brain abscess requiring neurosurgical
Signed Informed Consent
Covered by health insurance
Disqualifiers
Participant in exclusion period for another study
Participant referred to in articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons : pregnant woman, parturient, breastfeeding mother, person deprived of liberty by judicial or administrative decision, persons undergoing psychiatric care under articles L.3212-1 and L.3213-1 who do not fall under article L.1121-8, persons admitted to a healthcare or social institution for purposes other than research, minors, person under legal protection or unable to express consent).
Staff members with a hierarchical relationship to the principal investigator
Trial design
Single group
Treatments tested in this trial
Plasma Microbial Cell-Free DNA Metagenomic Sequencing
Diagnostic testA 20 mL peripheral blood sample will be collected prior to neurosurgical intervention for metagenomic next-generation sequencing (mNGS) analysis of circulating microbial cell-free DNA. Results will be compared with metagenomic analysis and conventional culture of intraoperative brain abscess specimens, which serve as the reference standard for microbiological identification.
Treatment groups
Trial outcomes
Primary outcomes
Blood and Brain Abscess Metagenomic Concordance
Comparison of bacterial species identified by metagenomic next-generation sequencing of cell-free DNA (cfDNA) from blood samples versus metagenomic analysis of per-operative brain abscess samples.
Secondary outcomes
Metagenomic Next-Generation Sequencing vs. Culture Concordance
Evaluation of bacterial species identification using metagenomic next-generation sequencing compared to gold-standard culture techniques on per-operative brain abscess samples.
Plasma Cell-Free DNA vs. Abscess Culture Correlation
Comparison of bacterial species identified by metagenomic analysis of circulating cell-free DNA (cfDNA) from blood samples versus species identified by conventional culture of per-operative brain abscess samples.
Potential Clinical Impact on Antimicrobial Treatment
Assessment of potential therapeutic modifications or antibiotic optimization induced by metagenomic next-generation sequencing results compared to standard culture-based diagnosis.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: